iPSC-based Drug Repurposing for ALS Medicine (iDReAM) Study
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
This is a phase 1, open-label, multicenter, dose escalation study to evaluate the safety and
tolerability of bosutinib to determine the maximum tolerated dose(MTD) and a recommended
phase 2 dose (RP2D) of bosutinib for treatment of ALS patients. Also, efficacy will be
evaluated exploratory.
Phase:
Phase 1
Details
Lead Sponsor:
Kyoto University
Collaborators:
Kitasato University Pfizer Tokushima University Tottori University